News and press

Therapeutic drug monitoring (TDM) of Infliximab (IFX) has been in use in our centre since 2012 and has become increasingly widespread in the UK with the availability of several CE marked assays. TDM of IFX is useful in optimisation of therapy in patients with inflammatory bowel disease (IBD). The detection of antibodies against Infliximab can guide clinical decision making with regard to dose escalation, immunomodulation or drug switching / withdrawal. However the utility of measuring free versus total (IFX-complex + free) anti-Infliximab antibody (ADAb) remains debatable, further complicated by lack of assay standardisation.

Our 2014 Financial Accounts signal another year of improved performance.

The last in our series for Cancer Awareness week features time lapse video and the latest on the new cancer facility at Guy’s Hospital.

In the next instalment of Viapath’s cancer awareness week, we discuss our expert, regional centre for solid cancer diagnostics.

Today, Viapath employees are using their heads to raise money for CLIC Sargent, the charity for children and young people with cancer.

Demystifying pathology - follow a haematology sample through the laboratory as we scratch the surface of diagnosing haematological malignancies.

This week, we will raise awareness of one of the UK’s biggest killers, demystify the process of diagnosing cancer and share the latest on London’s newest and most advanced Cancer Centre.

Demonstrating the scientific excellence of the people that make our organisation, our Reference Biochemistry Department at King's College Hospital have had two articles published within the same week.

Caty Delmont a Biomedical Scientist at King's College Hospital, recently travelled to Pakistan to teach laboratory skills at a women's hospital, working long hours and speaking in Urdu amongst other local languages!

Two of our laboratory experts made the short trip across the Capital to deliver a presentation to Year 7 students, discussing cells, tissues and organs and why healthcare science matters.